Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Search Results

Refine Your Search

By Sector

Sort by: Date|Relevance

Biotech Firm ''Creating Innovative Solutions' for Female Health

The company's most advanced assets are discussed in a Dawson James Securities report. In a July 18 research note, Dawson James Securities analyst Jason Kolbert reported he assumed coverage on Daré Bioscience Inc. (DARE:NASDAQ) , and in doing so, rated it Bu...

Health Tech Firm Completes Enrollment for Female Sexual Function Trial

A Ladenburg Thalmann report reviewed the study design and purpose. In March 11 research note, Ladenburg Thalmann analyst Jeffrey Cohen reported that Viveve Medical Inc. (VIVE:NASDAQ) finished enrollment for the VIVEVE II trial of 250 patients across 19 clinical locati...

Biopharma 'Keeps Executing and Securing Milestones'

The company's latest achievement and partnership potential are addressed in a ROTH Capital Partners report. In a Dec. 12 research note, ROTH Capital Partners analyst Yasmeen Rahimi reported that Daré Bioscience Inc. (DARE:NASDAQ) received U.S. Food and Drug Adminis...

Ultragenyx Shares Increase 30% on Results from Phase 1/2 OTC Deficiency Study

Rare disease biopharmaceutical company Ultragenyx Pharmaceutical's shares traded 30% higher after the firm reported positive topline results from Cohorts 2 and 3 in its Phase 1/2 study of DTX301 gene therapy in Ornithine Transcarbamylase Deficiency. After U.S. markets...

A Torchbearer to Guide the Way While Leading a New Frontier

(Click image to play video) It's 2021, and there are a plethora of cannabis companies operating out of America, but not all of them are alike. When it comes to the cannabis company Red White & Bloom Inc. (RWB) ( CSE.RWB , OTC:TDRY D, Forum ), the name it...

Gold Discoveries, Garimpeiros and a Gringo Bar

"Hello, you've reached Rock Bottom." It was the greeting for those calling Mongo's Rock Bottom Cafe, the popular expat bar opened by exploration geologist Dennis "Mongo" Moore and a partner in La Paz, Bolivia. That was in the early 1990s, before Bolivia became a rathe...

China’s Social Credit System - It’s Coming to the United States

In 2015, a 16-year-old student from Jiangsu, China, tried to board a train. She couldn’t even purchase a ticket. The student, Zhong Pei, tried enrolling in classes at her university. But she was not allowed to do that either.   Zhong had committed a serious ...

The Inflation–Deflation Conundrum

As I sit here on the shores of lovely Lake Scugog, its weed-infested waters lying in wait for countless unsuspecting propellers soon to be ensnared, I am reminded of the failed world of central banking and policy initiatives, which too has become ensnared in flora of its ...

Biotech Announces Deal with Bayer on Non-Hormonal Contraception

Details of the arrangement and an update on the company's pipeline are provided in a Dawson James report. In a Jan. 13 research note, Dawson James Securities analyst Jason Kolbert reported that Daré Bioscience Inc. (DARE:NASDAQ) partnered with Bayer, the company beh...

Mylan Gets a Shot in the Arm with Pfizer Merger Deal

EpiPen manufacturer Mylan N.V. announced today that the company will merge with Pfizer Inc.'s Upjohn Division, which holds Pfizer's off-patent branded and generic drugs, forming a new company. Mylan Inc. (MYL:NASDAQ) and Pfizer Inc. (PFE:NYSE) today anno...
1 2 3 4 5 6 7 8 9 10 ...